




Healthcare Industry News: Luminetx
News Release - March 18, 2009
Luminetx Names Chief Executive Officer
MEMPHIS, Tenn.--(HSMN NewsFeed)--Luminetx Corp. has named Richard Kindberg chief executive officer (CEO), after completing a thorough search for a top-notch medical device professional to lead the Memphis-based company’s executive team, and position Luminetx for the next phase of its company’s growth.“The Luminetx board is excited to bring a professional of this level to lead Luminetx going forward,” said Al Gossett, chairman of the Luminetx board. “2009 is going to be an important year for Luminetx, as we lay the foundation for continued growth to existing and new markets and Richard will lead that success. As interim CEO, it is a pleasure to hand over the reins to Richard as we have the utmost confidence in where he will take our company.”
Prior to joining Luminetx, Kindberg served as divisional president for Durham, North Carolina-based Teleflex Medical (NYSE: TFX ), a billion dollar medical device company where he had full operational responsibility. He’s also held numerous senior management positions at C.R. Bard, Optical Biopsy Technologies, Richard-Allan Medical, Focal Interventional and Johnson & Johnson.
“I am very excited to accept this appointment as CEO for Luminetx,” said Kindberg. “I feel the VeinViewer and Snowflake™ imaging technologies afford the company exciting new opportunities for expanded product line offerings in both the healthcare and biometrics markets. I look forward to working closely with the board of directors and Luminetx employees to continue to build our short- and long-term value for our shareholders and customers alike.”
About Luminetx
Based in Memphis, Tenn., Luminetx Corporation discovers, develops and commercializes medical product and biometric technologies. The company’s premier product, VeinViewer, is now available and in use nationwide. For more information on Luminetx and VeinViewer, visit www.Luminetx.com.
Source: Luminetx
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.